| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2afec86507fc41d4fd24a6693763f876 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 |
| filingDate |
2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7ac6207ef59447faee6e8c54978af12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf132291bc412a0aeee9c98ddec10d7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb9ca91ae51ed14d3e611f3828d61d80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20d2b66d2d4c4d118569c201a7f70049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e792a148b5be57edeb9934fdc4cbe9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ed33540ea788c260ded88a0852b6eee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08f8c3a4f69fe531b0a0ec1216e4f3c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c05b663085b6e97278336695ed0349a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_635f8b09cbd2f916ba30afeb740a663f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3485a0733ecf316852ceeb617b5755b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049514850cdecd19f92393e481327aee |
| publicationDate |
2020-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020405701-A1 |
| titleOfInvention |
Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof |
| abstract |
One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time. |
| priorityDate |
2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |